Cargando…
Secondary CNS myeloma with remission after systemic CNS-penetrating agents
BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radio...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307102/ https://www.ncbi.nlm.nih.gov/pubmed/35892045 http://dx.doi.org/10.1093/noajnl/vdac106 |
_version_ | 1784752688500572160 |
---|---|
author | Fernandez, Luis G Oyon, Daniel Eduardo Gondi, Vinai Grimm, Sean Khan, Osaama H |
author_facet | Fernandez, Luis G Oyon, Daniel Eduardo Gondi, Vinai Grimm, Sean Khan, Osaama H |
author_sort | Fernandez, Luis G |
collection | PubMed |
description | BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described. METHODS: We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment. RESULTS: The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone. CONCLUSIONS: This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules. |
format | Online Article Text |
id | pubmed-9307102 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-93071022022-07-25 Secondary CNS myeloma with remission after systemic CNS-penetrating agents Fernandez, Luis G Oyon, Daniel Eduardo Gondi, Vinai Grimm, Sean Khan, Osaama H Neurooncol Adv Clinical Investigations BACKGROUND: CNS myeloma is a rare manifestation of multiple myeloma and is often associated with a dismal prognosis; however, cases are increasing in frequency as overall survival improves for MM. There is currently no standardized treatment for CNS myeloma; however, different chemotherapy and radiotherapy regimens have been described. METHODS: We had previously reported on the efficacy of proton-based craniospinal irradiation in a patient with CNS myeloma; here we present a patient with a history of extramedullary plasmacytoma, 10 years in remission status post standard systemic chemotherapy, with biopsy-proven CNS myeloma successfully treated with systemic chemotherapy as a first-line treatment. RESULTS: The patient achieved clinical and radiographic remission on 2 separate occasions with systemic chemotherapy alone. CONCLUSIONS: This case demonstrates that systemically administered agents may have activity in CNS myeloma. Further investigations are necessary to establish the optimal combination of agents and treatment schedules. Oxford University Press 2022-07-01 /pmc/articles/PMC9307102/ /pubmed/35892045 http://dx.doi.org/10.1093/noajnl/vdac106 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Investigations Fernandez, Luis G Oyon, Daniel Eduardo Gondi, Vinai Grimm, Sean Khan, Osaama H Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title | Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title_full | Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title_fullStr | Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title_full_unstemmed | Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title_short | Secondary CNS myeloma with remission after systemic CNS-penetrating agents |
title_sort | secondary cns myeloma with remission after systemic cns-penetrating agents |
topic | Clinical Investigations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307102/ https://www.ncbi.nlm.nih.gov/pubmed/35892045 http://dx.doi.org/10.1093/noajnl/vdac106 |
work_keys_str_mv | AT fernandezluisg secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents AT oyondanieleduardo secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents AT gondivinai secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents AT grimmsean secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents AT khanosaamah secondarycnsmyelomawithremissionaftersystemiccnspenetratingagents |